Dario Announces Pricing of a $23.5 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
PR Newswire
NEW YORK, July 22, 2026
The financing was led by continued support of existing long-term institutional investors along with participation from a new global fundamental institutional investorNEW YORK, July 22, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company," "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced that it has entered into securities purchase agreements with current long term Dario institutional investors as well as new fundamental investors for the purchase and sale of 3,454,559 shares of common stock (or common stock equivalents in lieu thereof), at a price of $6.80 per share, in a registered direct offering priced at-the-market under Nasdaq rules (the "Offering"). A member of the Company's Board of Directors participated in the Offering by purchasing 14,430 shares of the Company's common stock at a purchase price of $6.93 per share. The gross proceeds from the Offering are expected to be approximately $23.5 million, before deducting placement agent fees and other estimated Offering expenses.
